Delcath Systems Announces Record Q3 Revenue and Provides 2026 Guidance
Delcath Systems (DCTH) reported record third-quarter revenue of $35.1 million, representing a significant 71% increase compared to the same period in 2025. This growth is primarily driven by the increasing market adoption of its HEPZATO KIT. Looking ahead, the company has provided revenue guidance for 2026 in the range of $115 million to $117 million. Management also aims to expand its commercial footprint by targeting at least 36 active treatment centers by the end of the year.
Tickers: $DCTH
Topics: earnings report medical devices revenue growth
Read the full article at Seeking Alpha
Part of the story Artmarket.com Announces Q3 2026 Revenue Growth and Upcoming Launch of AI-Driven Visual Search Tool (35 articles)